Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

enGene Holdings Inc. ENGN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score
46/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$24.60
+217%

enGene Holdings Inc. (ENGN) is a Biotechnology company in the Healthcare sector, currently trading at $7.76. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is ENGN = $25 (+217% upside).

Valuation: ENGN trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.14.

Net income is $117M (loss), growing at -155.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $32M against $168M equity (Debt-to-Equity (D/E) ratio 0.19, conservative). Current ratio is 6.3 (strong liquidity). Debt-to-assets is 14.4%. Total assets: $221M.

Analyst outlook: 5 / 6 analysts rate ENGN as buy (83%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 48/100 (Partial), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$24.60
▲ 217.01% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for enGene Holdings Inc., the average price target is $24.60, with a high forecast of $33.00, and a low forecast of $10.00.
Highest Price Target
$33.00
Average Price Target
$24.60
Lowest Price Target
$10.00

ENGN SharesGrow Score Overview

46/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 48/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ENGN

~
VALUE Partial
48/100
ENGN trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25). Forward PEG 3.14 — overvalued. Analyst consensus target is $25, implying +222.2% from the current price $8. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ENGN: +0%/yr revenue is, -155.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
ENGN: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet ENGN: Debt-to-Equity (D/E) ratio 0.19 (conservative), Current ratio is 6.3 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ENGN: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 5 / 6 analysts rate ENGN as buy (83%). Analyst consensus target is $25 (+222.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.65-12.25
Volume211.07K
Avg Volume (30D)415.43K
Market Cap$397.27M
Beta (1Y)-0.05
Share Statistics
EPS (TTM)-2.29
Shares Outstanding$51.12M
IPO Date2022-02-01
Employees56
CEORonald H. W. Cooper
Financial Highlights & Ratios
EBITDA$-113.8M
Net Income$-117.3M
Operating Income$-123.17M
Total Cash$193.82M
Total Debt$31.8M
Net Debt$-18.36M
Total Assets$221.47M
Price / Earnings (P/E)-3.4
Analyst Forecast
1Y Price Target$27.00
Target High$33.00
Target Low$10.00
Upside+247.9%
Rating ConsensusBuy
Analysts Covering6
Buy 83% Hold 17% Sell 0%
Price Target Summary
Company Info
CountryCA
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINCA29286M1059

Price Chart

Track all markets on TradingView
ENGN
enGene Holdings Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
2.65 52WK RANGE 12.25

People Also View

ANRO
ANRO
Alto Neuroscience, Inc.
$25.47
-1.36%
 ANNX
ANNX
Annexon, Inc.
$6.35
+9.48%
 DBVT
DBVT
DBV Technologies S.A.
$21.25
-1.80%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.83
-0.82%
 CLLS
CLLS
Cellectis S.A.
$4.09
-1.68%
 SLN
SLN
Silence Therapeutics plc
$7.28
+18.95%
 ACIU
ACIU
AC Immune S.A.
$3.14
-1.57%
 AMRN
AMRN
Amarin Corporation plc
$15.20
+4.47%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message